Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Given Consensus Rating of “Hold” by Analysts

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) have earned an average recommendation of “Hold” from the twenty-three brokerages that are presently covering the stock, MarketBeat reports. Three analysts have rated the stock with a sell recommendation, twelve have issued a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $102.70.

A number of equities research analysts recently weighed in on the company. Leerink Partners began coverage on Zimmer Biomet in a research note on Monday, April 13th. They set a “hold” rating and a $101.00 price objective for the company. Wall Street Zen upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Truist Financial reiterated a “hold” rating and set a $92.00 price objective (down from $98.00) on shares of Zimmer Biomet in a research note on Wednesday, April 29th. Canaccord Genuity Group set a $83.00 price objective on shares of Zimmer Biomet in a research note on Wednesday, April 29th. Finally, BTIG Research reiterated a “neutral” rating on shares of Zimmer Biomet in a research note on Monday, March 23rd.

Insider Buying and Selling

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of the stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the sale, the insider directly owned 27,251 shares in the company, valued at approximately $2,252,022.64. This trade represents a 15.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 1.28% of the company’s stock.

Institutional Investors Weigh In On Zimmer Biomet

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ZBH. DV Equities LLC purchased a new stake in Zimmer Biomet in the fourth quarter valued at about $25,000. Monetary Solutions Ltd purchased a new stake in Zimmer Biomet in the fourth quarter valued at about $30,000. Gen Wealth Partners Inc purchased a new stake in Zimmer Biomet in the fourth quarter valued at about $31,000. Flagship Harbor Advisors LLC purchased a new stake in Zimmer Biomet in the fourth quarter valued at about $32,000. Finally, Grove Bank & Trust raised its stake in Zimmer Biomet by 431.6% in the fourth quarter. Grove Bank & Trust now owns 404 shares of the medical equipment provider’s stock valued at $36,000 after buying an additional 328 shares during the last quarter. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Zimmer Biomet Price Performance

ZBH opened at $88.54 on Friday. Zimmer Biomet has a 12-month low of $79.12 and a 12-month high of $108.29. The company has a current ratio of 1.73, a quick ratio of 0.95 and a debt-to-equity ratio of 0.50. The business’s fifty day simple moving average is $87.56 and its 200-day simple moving average is $90.43. The company has a market capitalization of $17.13 billion, a price-to-earnings ratio of 23.00, a PEG ratio of 2.05 and a beta of 0.47.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.86 by $0.23. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The business had revenue of $2.09 billion for the quarter, compared to the consensus estimate of $2.07 billion. During the same quarter in the prior year, the company earned $1.81 EPS. The business’s revenue was up 9.3% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. On average, equities research analysts anticipate that Zimmer Biomet will post 8.49 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Thursday, June 25th will be paid a $0.24 dividend. The ex-dividend date is Thursday, June 25th. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. Zimmer Biomet’s dividend payout ratio (DPR) is 24.94%.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.